Company News: Page (1) of 1 - 06/05/18 Email this story to a friend. email article Print this page (Article printing at page facebook

Stemline Therapeutics Announces Positive Data Presentations on SL-701 and SL-801 at ASCO

(June 05, 2018)

NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that positive data from the SL-701 and SL-801 clinical trials were presented at the 2018 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL. The presentations are available on Stemline’s website ( under the Scientific Presentations tab.

SL-701 – Clinical Highlights

  • The Phase 2 trial of SL-701 in previously treated GBM patients met its primary endpoint of 12-month overall survival (OS-12)

    Page: 1

    Related Keywords:


Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved